Shiffman, Mitchell L.

Publishing since 1990 (Dinosaur)

Has published 176 publications in 21 years

Number of publications published per year by Shiffman, Mitchell L.. (Source : PubMed)

Distribution of publications types for Shiffman, Mitchell L.. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, Shiffman ML, Fontana RJ, Di Bisceglie AM, Bonkovsky HL, Dienstag JL. Complication Rate of Percutaneous Liver Biopsies among Persons with Advanced Chronic Liver Disease in the HALT-C Trial.  Clin. Gastroenterol. Hepatol.  2010  
•  Hu KQ, Schiff ER, Kowdley KV, Min AD, Shiffman ML, Lee WM, Goodman ZD, Dau LO, Peschell KJ, Fagan EA, Flaherty JF. Histologic Evidence of Active Liver Injury in Chronic Hepatitis B Patients With Normal Range or Minimally Elevated Alanine Aminotransferase Levels.  J. Clin. Gastroenterol.  2010  
•  Shiffman ML, Pockros P, McHutchison JG, Schiff ER, Morris M, Burgess G. Clinical trial: efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C.  Aliment. Pharmacol. Ther.  2010  
•  Bruno S, Shiffman ML, Roberts SK, Gane EJ, Messinger D, Hadziyannis SJ, Marcellin P. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis.  Hepatology  2010;51;2  
•  Shiffman ML. Management of acute hepatitis B.  Clin Liver Dis  2010;14;1  
•  Diago M, Shiffman ML, Bronowicki JP, Zeuzem S, Rodriguez-Torres M, Pappas SC, Tietz A, Nelson DR. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin.  Hepatology  2010  
•  Goodman ZD, Stoddard AM, Bonkovsky HL, Fontana RJ, Ghany MG, Morgan TR, Wright EC, Brunt EM, Kleiner DE, Shiffman ML, Everson GT, Lindsay KL, Dienstag JL, Morishima C. Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial.  Hepatology  2009;50;6  
•  Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC, Naishadham D, Everson GT, Lok AS, Di Bisceglie AM, Bonkovsky HL, Ghany MG. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.  Gastroenterology  2009;137;6  
•  Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima C, Abnet CC, Sinha R. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C.  Hepatology  2009;50;5  
•  Benhamou Y, Afdhal NH, Nelson DR, Shiffman ML, Halliman DG, Heise J, Chun E, Pockros PJ. A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results.  Hepatology  2009;50;3  

[ See timeline ] [ See all publications ]